SemBioSys' GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil



    TSX symbol: SBS

    CALGARY, March 14 /CNW/ - SemBioSys Genetics Inc. (TSX: SBS), a
biotechnology company developing a portfolio of therapeutic proteins for
metabolic and cardiovascular diseases, today announced that Arcadia
Biosciences, Inc., made an important step forward in the commercialization of
High GLA Safflower Oil. Arcadia entered into an exclusive global alliance with
Bioriginal Food and Science Corp., to market and distribute High GLA Safflower
Oil, an omega-6 polyunsaturated fatty acid with proven heath benefits, as a
nutritional supplement and food ingredient. SemBioSys was contracted by
Arcadia to utilize Arcadia's proprietary genes and SemBioSys' promoters and
safflower transformation technology to produce and deliver safflower seed
lines containing more than 40 percent GLA. Under the agreement, SemBioSys
receives milestone payments upon the successful scale-up of GLA safflower
lines as well as royalties from commercial sales.
    GLA (gamma linolenic acid) is an omega-6 polyunsaturated fatty acid
which, along with omega-3 fatty acids, has demonstrated health benefits. GLA's
clinically-validated benefits include anti-inflammatory effects and improved
skin health and appearance. Existing commercial sources of GLA, evening
primrose oil and borage oil, contain 10 or 20-23 percent GLA, respectively.
With a GLA content of 40 percent, Arcadia's high-GLA safflower oil would
significantly reduce the daily consumption of GLA oil capsules and make it
more convenient and affordable for consumers. According to ICIS Chemical
Business Americas, the U.S. market for GLA oils is currently valued at more
than US$100 million. With a more convenient, more highly concentrated source
of GLA, Arcadia believes the market can grow beyond this figure.
    "Nutritional supplements and nutraceuticals are a growing market as
health conscious consumers are increasingly choosing to augment their diet
with nutrients that have proven health benefits. Arcadia's high-GLA safflower
oil is a convenient and cost-effective source of GLA compared to existing
alternatives," said Andrew Baum, President and CEO of SemBioSys.

    About SemBioSys Genetics Inc. (www.sembiosys.com)

    Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company
developing protein-based pharmaceuticals for metabolic and cardiovascular
diseases. The Company's lead pharmaceutical candidates are recombinant human
insulin to serve the rapidly expanding global diabetes market and Apo AI, a
next generation cardiovascular drug. In addition to its pharmaceutical
products, SemBioSys is developing a series of non-pharmaceutical products
addressing human topical, nutritional oils and agricultural biotechnology
markets.

    About Arcadia Biosciences, Inc.

    Based in Davis, Calif., with additional facilities in Seattle, Wash. and
Phoenix, Ariz., Arcadia Biosciences is an agricultural biotechnology company
focused on the development of agricultural products that improve the
environment and enhance human health. For more information visit
www.arcadiabio.com.

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at www.sedar.com. Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.





For further information:

For further information: SemBioSys Genetics Inc., Mr. Andrew Baum,
President and Chief Executive Officer, Phone: (403) 717-8767, Fax: (403)
250-3886, E-mail: bauma@sembiosys.com, Internet: www.sembiosys.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700, (Ext.
238), Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com; Arcadia
Biosciences, Inc., Jeff Bergau, Phone: (312) 217-0419, E-mail:
jeff.bergau@arcadiabio.com, Internet: www.arcadiabio.com

Organization Profile

SemBioSys Genetics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890